**
Emerging research from the American Society of Clinical Oncology meeting in Chicago indicates a potentially transformative connection between GLP-1 medications and reduced cancer risks. This compelling development comes as semaglutide, a prominent GLP-1 drug, becomes increasingly available in Canada, with generic versions now reaching pharmacies. The findings suggest that these weight-loss drugs may not only aid in obesity management but also play a significant role in cancer prevention.
GLP-1 Drugs and Cancer: What the Research Reveals
A series of studies unveiled at the conference highlighted a notable trend: patients treated with GLP-1 drugs exhibited lower rates of cancer diagnosis and disease progression compared to those who did not use these medications. Dr. Judith Bray, vice-president of research at the Canadian Cancer Society, remarked on the importance of the findings, describing them as “transformative.” She reflected on the growing awareness within the research community, stating, “The whole research world woke up” to the potential implications of these drugs.
One pivotal study conducted by American researchers examined data from over 161,000 patients, primarily those who were obese but did not have diabetes or a history of obesity-related cancer. The participants were divided into two groups: one received weight-loss injections, while the other received dietary and exercise consultations over two years. Results revealed that the group using GLP-1 medications had a 41 per cent lower risk of being diagnosed with obesity-related cancers during the follow-up period, a statistic that underscores the potential of these drugs in cancer prevention.
Breast Cancer and GLP-1: A Promising Connection
In another significant study presented on June 2, researchers explored the relationship between GLP-1 treatments and breast cancer incidence. The research, published in the JCO Oncology Practice, involved over 110,000 women aged 45 to 80 who underwent breast imaging between January 2022 and June 2025. The study found that nearly 14 per cent of participants had been prescribed GLP-1 medications, and those women demonstrated up to a 35 per cent lower risk of developing breast cancer compared to their non-user counterparts.
To further validate these results, a matched analysis was conducted comparing more than 15,000 women on GLP-1 drugs with similar women who were not. The findings indicated that those on GLP-1 medications had nearly a 31 per cent lower likelihood of being diagnosed with breast cancer. While the study was observational and does not definitively establish a causal link, lead researcher Dr. Elizabeth McDonald emphasised the need for further investigation into these medications as potential cancer prevention tools.
The Call for Canadian Research
The implications of these findings are particularly relevant in Canada, where recent statistics indicate that over two-thirds of adults aged 18 to 79 now have a body mass index classified as overweight or obese, up from 60 per cent prior to the COVID-19 pandemic. Kimberly Carson, CEO of Breast Cancer Canada, expressed optimism about the research, stating, “This is very encouraging… It’s exciting moving forward, and I really love the progress we’re making here.”
Carson also advocated for further Canadian research on the subject, noting the absence of local data. “I think we have the capacity to run a study like this in Canada, and there’s an opportunity for us to contribute to this important area of research,” she asserted. Given the projected rise in breast cancer diagnoses, the pursuit of understanding the anti-cancer potential of GLP-1 drugs could not be more timely.
Why it Matters
As the dialogue around obesity and cancer continues to evolve, these promising findings offer a beacon of hope for patients and healthcare providers alike. If further research substantiates the links between GLP-1 medications and reduced cancer risk, it could herald a new era in preventative healthcare strategies. By harnessing the potential of these drugs, we may not only address the obesity epidemic but also take significant strides toward reducing cancer incidence, ultimately improving health outcomes for countless individuals. The pathway ahead calls for robust Canadian studies to explore these possibilities further, ensuring that the nation remains at the forefront of advancements in cancer prevention and treatment.
